For research use only. Not for therapeutic Use.
Balaglitazone(CAT: I002528) is a selective partial agonist of the peroxisome proliferator-activated receptor gamma (PPAR-γ), widely used in metabolic and diabetes research. This thiazolidinedione derivative is designed to improve insulin sensitivity with reduced side effects compared to full PPAR-γ agonists. Balaglitazone is particularly valuable for investigating its role in glucose homeostasis, lipid metabolism, and inflammation. Researchers explore its therapeutic potential in managing type 2 diabetes mellitus and associated metabolic disorders. Its balanced activity and reduced adverse effects make Balaglitazone a critical tool for preclinical studies focused on developing safer and more effective treatments for metabolic diseases.
| Catalog Number | I002528 |
| CAS Number | 199113-98-9 |
| Synonyms | 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| Molecular Formula | C20H17N3O4S |
| Purity | ≥95% |
| Target | Vitamin D Related/Nuclear Receptor |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| InChI | InChI=1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,16H,10-11H2,1H3,(H,22,24,26) |
| InChIKey | IETKPTYAGKZLKY-UHFFFAOYSA-N |
| SMILES | CN1C(=NC2=CC=CC=C2C1=O)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4 |
